Tom 12, Nr 3 (2017)
NIEWYDOLNOŚĆ SERCA
Opublikowany online: 2017-08-02
Wyświetlenia strony
1650
Wyświetlenia/pobrania artykułu
20185
Zapalenie mięśnia sercowego
Kardiol Inwazyjna 2017;12(3):47-58.
Streszczenie
Zapalenie mięśnia sercowego (ZMS) powstaje w wyniku zakażeń, działania leków, toksycznych substancji lub jest związane z chorobami autoimmunologicznymi. Etiologia wirusowa jest najczęstszą przyczyną ZMS. Obecnie parwowirus B19, human herpesvirus 6 (HHV-6) i cytomegalowirus są najczęściej wykrywanymi wirusami w miokardium objętym procesem zapalnym. Ze względu na niespecyficzne objawy, rozpoznanie ZMS może być problematyczne. Ponadto nieinwazyjne metody obrazowania, takie jak echokardiografia i rezonans magnetyczny serca nie pozwalają na postawienie ostatecznej diagnozy. Złotym standardem w rozpoznaniu ZMS pozostaje biopsja endomiokardialna. Pozwala ona na ocenę histologiczną, immunohistochemiczną i molekularną. Identyfikacja czynnika etiologicznego jest istotna, ponieważ umożliwia włączenie specyficznego leczenia przeciwwirusowego, które poprawia rokowanie.
Słowa kluczowe: zapalenie mięśnia serowego
Referencje
- Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012; 59(9): 779–792.
- Felker G, Hu W, Hare J, et al. The Spectrum of Dilated Cardiomyopathy: The Johns Hopkins Experience with 1,278 Patients. Medicine. 1999; 78(4): 270–283.
- Gil KE, Pawlak A, Gil RJ, et al. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci. 2016; 61(2): 331–343.
- Caforio ALP, Pankuweit S, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013; 34(33): 2636–48, 2648a.
- Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev. 2013; 18(6): 761–795.
- Andréoletti L, Lévêque N, Boulagnon C, et al. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009; 102(6-7): 559–568.
- Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005; 111(7): 887–893.
- Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005; 112(13): 1965–1970.
- Maisch B, Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz. 2012; 37(6): 644–656.
- Klein RM, Jiang H, Niederacher D, et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol. 2004; 93(4): 300–309.
- Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006; 114(15): 1581–1590.
- Pankuweit S, Klingel K. Viral myocarditis: from experimental models to molecular diagnosis in patients. Heart Fail Rev. 2013; 18(6): 683–702.
- Krueger GRF, Ablashi DV. Human herpesvirus-6: a short review of its biological behavior. Intervirology. 2003; 46(5): 257–269.
- Kühl U, Schultheiss HP. Viral myocarditis. Swiss Med Wkly. 2014; 144: w14010.
- Kandolf R, Bültmann B, Klingel K, et al. [Molecular mechanisms and consequences of cardiac viral infections]. Pathologe. 2008; 29 Suppl 2: 112–117.
- Bowles N, Ni J, Kearney D, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. J Am Coll Cardiol. 2003; 42(3): 466–472.
- Kytö V, Vuorinen T, Saukko P, et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Clin Infect Dis. 2005; 40(5): 683–688.
- Calabrese F, Carturan E, Chimenti C, et al. Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol. 2004; 17(9): 1108–1118.
- Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol. 2008; 130(3): 304–309.
- Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine. 2008; 26 Suppl 4: D59–D66.
- Gdynia G, Schnitzler P, Brunner E, et al. Sudden death of an immunocompetent young adult caused by novel (swine origin) influenza A/H1N1-associated myocarditis. Virchows Arch. 2011; 458(3): 371–376.
- Matsumori A, Shimada T, Chapman NM, et al. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail. 2006; 12(4): 293–298.
- Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006; 151(6): 1147–1155.
- Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006; 113(6): 876–890.
- Barbaro G, Di Lorenzo G, Grisorio B, et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med. 1998; 339(16): 1093–1099.
- Wasi F, Shuter J. Primary bacterial infection of the myocardium. Front Biosci. 2003; 8: s228–s231.
- Michira BN, Alkizim FO, Matheka DM. Patterns and clinical manifestations of tuberculous myocarditis: a systematic review of cases. Pan Afr Med J. 2015; 21: 118.
- Dutly F, Altwegg M. Whipple's disease and "Tropheryma whippelii". Clin Microbiol Rev. 2001; 14(3): 561–583.
- Palecek T, Kuchynka P, Hulinska D, et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Med Microbiol Immunol. 2010; 199(2): 139–143.
- Aiello VD, de Campos FP. Chronic Chagas cardiomyopathy. Autops Case Rep. 2015; 5(3): 7–9.
- Maisch B, Ruppert V, Pankuweit S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options. Curr Heart Fail Rep. 2014; 11(2): 166–177.
- Grogan M, Redfield MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995; 26(1): 80–84.
- Schultheiss H-P, Noutsias M. Inflammatory Cardiomyopathy (DCMi) — Pathogenesis and Therapy. Ed. 1. Progress in Inflammation Research. Birkhäuser, Basel 2010.
- Maze SS, Adolph RJ. Myocarditis: unresolved issues in diagnosis and treatment. Clin Cardiol. 1990; 13(2): 69–79.
- Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000; 25(3): 279–285.
- Dec GWJr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985; 312(14): 885–890.
- Schultz JC, Hilliard AA, Cooper LT, et al. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009; 84(11): 1001–1009.
- Caforio ALP, Marcolongo R, Basso C, et al. Clinical presentation and diagnosis of myocarditis. Heart. 2015; 101(16): 1332–1344.
- Dominguez F, Kühl U, Pieske B, et al. Update on Myocarditis and Inflammatory Cardiomyopathy: Reemergence of Endomyocardial Biopsy. Rev Esp Cardiol (Engl Ed). 2016; 69(2): 178–187.
- Caforio ALP, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008; 41(1): 35–45.
- Elamm C, Fairweather D, Cooper LT. Pathogenesis and diagnosis of myocarditis. Heart. 2012; 98(11): 835–840.
- Wang K, Asinger RW, Marriott HJL. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med. 2003; 349(22): 2128–2135.
- Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008; 29(17): 2073–2082.
- Liu PP, Yan AT. Cardiovascular magnetic resonance for the diagnosis of acute myocarditis: prospects for detecting myocardial inflammation. J Am Coll Cardiol. 2005; 45(11): 1823–1825.
- Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010; 52(4): 274–288.
- Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000; 36(1): 227–232.
- Petryka J, Miśko J, Małek LA, et al. [Cardiovascular magnetic resonance in the diagnosis of myocarditis]. Kardiol Pol. 2010; 68(7): 824–829.
- Hunold P, Schlosser T, Vogt FM, et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol. 2005; 184(5): 1420–1426.
- Friedrich MG, Sechtem U, Schulz-Menger J, et al. International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009; 53(17): 1475–1487.
- Abdel-Aty H, Zagrosek A, Schulz-Menger J, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004; 109(20): 2411–2416.
- Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006; 113(15): 1865–1870.
- Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007; 50(19): 1914–1931.
- Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010; 122(9): 900–909.
- Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987; 18(6): 619–624.
- Kühl U, Lassner D, von Schlippenbach J, et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012; 60(14): 1295–1296.
- Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011; 32(21): 2616–2625.
- Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29(19): 2388–2442.
- Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53(15): e1–e90.
- Rezkalla SH, Raikar S, Kloner RA. Treatment of viral myocarditis with focus on captopril. Am J Cardiol. 1996; 77(8): 634–637.
- Saegusa S, Fei Yu, Takahashi T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther. 2007; 21(3): 155–160.
- Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003; 107(22): 2793–2798.
- Schmidt-Lucke C, Spillmann F, Bock T, et al. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus b19 infection. J Infect Dis. 2010; 201(6): 936–945.
- Kühl U, Lassner D, Wallaschek N, et al. Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment. Eur J Heart Fail. 2015; 17(1): 9–19.
- Jühl U, Strauer BE, Schultheiss HP. Methylprednisolone in chronic myocarditis. Postgrad Med J. 1994; 70 Suppl 1: S35–S42.
- Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003; 107(6): 857–863.
- Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009; 30(16): 1995–2002.
- Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994; 89(1): 252–257.
- McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103(18): 2254–2259.
- Klugman D, Berger JT, Sable CA, et al. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol. 2010; 31(2): 222–228.
- Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002; 39(4): 646–652.
